HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
HCW Biologics Inc. (HCWB)
Company Research
Source: GlobeNewswire
Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities IND application expected to be filed in first half of 2027 to seek authorization for clinical study in patients with pancreatic cancer Poster presented at the American Association of Cancer Research Annual Meeting 2026 MIRAMAR, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation announced today major development regarding its tetra-valent, second-generation T-Cell Engager Program (the “Big BiTE”) based on its TRBC platform technology, was presented at the poster session at the American Association of Cancer Research (“AACR”) Annual Meeting 2026, which took place from April 17 – 22, 2026 in San Diego, California.
Show less
Read more
Impact Snapshot
Event Time:
HCWB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HCWB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HCWB alerts
High impacting HCW Biologics Inc. news events
Weekly update
A roundup of the hottest topics
HCWB
News
- HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results [TheStreet.com]TheStreet.com
- HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial ResultsGlobeNewswire
- HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic [Yahoo! Finance]Yahoo! Finance
- HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion ImmunotherapeuticGlobeNewswire
- BC-Most Active Stocks [Yahoo! Finance]Yahoo! Finance
HCWB
Sec Filings
- 4/29/26 - Form DEF
- 4/28/26 - Form ARS
- 4/24/26 - Form S-1/A
- HCWB's page on the SEC website